NCT02203149View on ClinicalTrials.gov

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

August 1, 2014

Primary Completion Date

October 2, 2015

Study Completion Date

May 16, 2016

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir

One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

DRUG

Elbasvir

One 50 mg tablet taken orally once daily for 12 weeks.

DRUG

Placebo to Grazoprevir

One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.

DRUG

Placebo to Elbasvir

One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02203149 - Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058) | Biotech Hunter | Biotech Hunter